ArticleBrain, behavior, & immunity - health2026
Preliminary evidence of neuroimmune system disruption in opioid use disorder: Findings from a pilot PET TSPO imaging study.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preclinical and postmortem human studies demonstrate significant opioid-related alterations in the neuroimmune system. However, studies investigating the neuroimmune system in living people with opioid use disorder (OUD) are lacking, thereby motivating this pilot study. Methods: Individuals with OUD (n = 6; DSM-5 criteria) were admitted inpatient and stabilized on an individualized buprenorphine dose for 5 to 10 days before a 120-min Positron Emission Tomography (PET) [ Results: OUD participants exhibited higher brain TSPO availability by 20% across ROIs, on average (range: 12-22%) relative to non-OUD comparators (Group Effect; Conclusions: Results are the first exploratory evidence that living participants with OUD, stabilized on buprenorphine inpatient, exhibit elevated TSPO availability, an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.